Can neutrophil/lymphocyte ratio and platelet/lymphocyte ratio be used in differential diagnosis of Stage I sarcoidosis from tuberculosis lymphadenopathy?
There were neither significantdifferences in serum NLR nor PLR between sarcoidosis and TB groups.CONCLUSION: Although NLR and PLR are useful tools to differentiate Stage 1 sarcoidosis fromcontrols and PLR may be used to differentiate TB lymphadenopathy from controls, these parametersmay not be used to differentiate between Stage 1 sarcoidosis and TB lymphadenopathy.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:OBJECTIVE: It is challenging to differentiate mediastinal lymph node enlargement caused bytuberculosis (TB) and sarcoidosis as both diseases may cause granulomatous inflammation.The objective of this study is to evaluate the use of neutrophil/lymphocyte ratio (NLR) andplatelet/lymphocyte ratio (PLR) as possible markers in the differential diagnosis of Stage I sarcoidosisand TB lymphadenopathy in patients who present with mediastinal lymph nodes and no parenchymalinvolvement.MATERIALS AND METHODS: A total of 19 TB, 55 sarcoidosis, and 32 control patients, whose clinicalrecords were available, were included in this retrospective study.
📊
Key Findings & Data:The complete blood count at the time ofdiagnosis was included in the study.RESULTS: NLR and PLR were both significantly increased in Stage 1 sarcoidosis patients comparedto controls while only PLR was significantly increased in the TB group (for sarcoidosis, NLRP < 0.001 and PLR P < 0.001; for TB, NLR P = 0.12; PLR P = 0.017).
💡
Conclusion & Impact:There were neither significantdifferences in serum NLR nor PLR between sarcoidosis and TB groups.CONCLUSION: Although NLR and PLR are useful tools to differentiate Stage 1 sarcoidosis fromcontrols and PLR may be used to differentiate TB lymphadenopathy from controls, these parametersmay not be used to differentiate between Stage 1 sarcoidosis and TB lymphadenopathy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
OBJECTIVE: It is challenging to differentiate mediastinal lymph node enlargement caused bytuberculosis (TB) and sarcoidosis as both diseases may cause granulomatous inflammation.The objective of this study is to evaluate the use of neutrophil/lymphocyte ratio (NLR) andplatelet/lymphocyte ratio (PLR) as possible markers in the differential diagnosis of Stage I sarcoidosisand TB lymphadenopathy in patients who present with mediastinal lymph nodes and no parenchymalinvolvement.MATERIALS AND METHODS: A total of 19 TB, 55 sarcoidosis, and 32 control patients, whose clinicalrecords were available, were included in this retrospective study. All patients had a granulomatousreaction revealed on their lymph node biopsy specimen. The complete blood count at the time ofdiagnosis was included in the study.RESULTS: NLR and PLR were both significantly increased in Stage 1 sarcoidosis patients comparedto controls while only PLR was significantly increased in the TB group (for sarcoidosis, NLRP < 0.001 and PLR P < 0.001; for TB, NLR P = 0.12; PLR P = 0.017). There were neither significantdifferences in serum NLR nor PLR between sarcoidosis and TB groups.CONCLUSION: Although NLR and PLR are useful tools to differentiate Stage 1 sarcoidosis fromcontrols and PLR may be used to differentiate TB lymphadenopathy from controls, these parametersmay not be used to differentiate between Stage 1 sarcoidosis and TB lymphadenopathy.
🔖
Cite This Article
Sökücü, S. N., Önür, S. T., Özdemir, C. (2022). Can neutrophil/lymphocyte ratio and platelet/lymphocyte ratio be used in differential diagnosis of Stage I sarcoidosis from tuberculosis lymphadenopathy?. Eurasian Journal of Pulmonology, Cilt: 20 - Sayı: 1, 22–26. https://ajindex.com/articles/509689
Asano S. Granulomatous lymphadenitis. J Clin Exp Hematopathol 2012;52:1‑16
WHO. Global Tuberculosis Control 2014. Available from: http:// www.who.int/tb/publications/global_report/2014/gtbr11_full. pdf. [Last accessed on 2014 Dec 14]
WHO’s Global TB Database. Available from: http://www.who. int/tb/country/data/profiles/en. [Last accessed on 2015 Jan 22]
Golden MP, Vikram HR. Extrapulmonary tuberculosis: An overview. Am Fam Physician 2005;72:1761‑8
Ilgazli A, Boyaci H, Basyigit I, Yildiz F. Extrapulmonary tuberculosis: Clinical and epidemiologic spectrum of 636 cases. Arch Med Res 2004;35:435‑41
Statement on sarcoidosis. Joint statement of the american thoracic society (ATS), the european respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med 1999;160:736‑55
Telenti A, Hermans PE. Idiopathic granulomatosis manifesting as fever of unknown origin. Mayo Clin Proc 1989;64:44‑50
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ, et al. The systemic inflammation‑based neutrophil‑lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218‑30
Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLO in various cancers: A meta‑analysis. PLoS One 2014;9:e101119
Dirican N, Anar C, Kaya S, Bircan HA, Colar HH, Cakir M, et al. The clinical significance of hematologic parameters in patients with sarcoidosis. Clin Respir J 2016;10:32‑9
Iliaz S, Iliaz R, Ortakoylu G, Bahadir A, Bagci BA, Caglar E, et al. Value of neutrophil/lymphocyte ratio in the differential diagnosis of sarcoidosis and tuberculosis. Ann Thorac Med 2014;9:232‑5
Günay E, Sarınç Ulaşlı S, Akar O, Ahsen A, Günay S, Koyuncu T, et al. Neutrophil‑to‑lymphocyte ratio in chronic obstructive pulmonary disease: A retrospective study. Inflammation 2014;37:374‑80. 13. d e J a g e r C P, W e v e r P C, G e m e n E F, K u s t e r s R, v a n G a g e l d o n k ‑ L a f e b e r A B, v a n d e r P o l l T, et a l. The neutrophil‑lymphocyte count ratio in patients with community‑acquired pneumonia. PLoS One 2012;7:e46561
Yoon NB, Son C, Um SJ. Role of the neutrophil‑lymphocyte count ratio in the differential diagnosis between pulmonary tuberculosis and bacterial community‑acquired pneumonia. Ann Lab Med 2013;33:105‑10